Ets1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory pc3 prostate cancer cells by up-regulating mdr1 and mmp9 expression

Biochemical and Biophysical Research Communications

Volumn 417, Issue 3, 2012, Pages 966-971

  Kato, Taku ^a,b   Fujita, Yasunori ^b,c   Nakane, Keita ^a,b   Kojima, Toshio ^d   Nozawa, Yoshinori ^b,e   Deguchi, Takashi ^a   Ito, Masafumi ^b,c  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Tokai Women's Junior College   (Japan)

Author keywords

ETS1; MDR1; Metastasis; MMP9; Paclitaxel resistance; Prostate cancer

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; STROMELYSIN; TRANSCRIPTION FACTOR ETS 1; UROKINASE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INVASION; CANCER RESISTANCE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HORMONE RESISTANCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; P-GLYCOPROTEIN; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEIN C-ETS-1; UP-REGULATION;

EID: 84856018330     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.047     Document Type: Article

References (26)

1. Wasylyk B., Hahn S.L., Giovane A. The Ets family of transcription factors. Eur. J. Biochem. 1993, 211:7-18.
2. Kars M.D., Iseri O.D., Gunduz U. Drug resistant breast cancer cells overexpress ETS1 gene. Biomed. Pharmacother. 2010, 64:458-462.
3. Khanna A., Mahalingam K., Chakrabarti D., Periyasamy G. Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cell. Mol. Biol. Lett. 2011, 16:101-113.
4. Wilson L.A., Yamamoto H., Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol. Cancer Ther. 2004, 3:823-832.
5. Nagarajan P., Parikh N., Garrett-Sinha L.A., Sinha S. Ets1 induces dysplastic changes when expressed in terminally-differentiating squamous epidermal cells. PLoS One 2009, 4:e4179.
6. Alipov G., Nakayama T., Ito M., Kawai K., Naito S., Nakashima M., Niino D., Sekine I. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 2005, 46:202-208.
7. Deuchars K.L., Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Sem. Oncol. 1989, 16:156-165.
8. Amalinei C., Caruntu I.D., Giusca S.E., Balan R.A. Matrix metalloproteinases involvement in pathologic conditions. Rom. J. Morphol. Embryol. 2010, 51:215-228.
9. Andreasen P.A., Kjoller L., Christensen L., Duffy M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72:1-22.
10. Shi Z., Stack M.S. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem. J. 2007, 407:153-159.
11. Sampath J., Sun D., Kidd V.J., Grenet J., Gandhi A., Shapiro L.H., Wang Q., Zambetti G.P., Schuetz J.D. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J. Biol. Chem. 2001, 276:39359-39367.
12. Baillat D., Begue A., Stehelin D., Aumercier M. ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition. J. Biol. Chem. 2002, 277:29386-29398.
13. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H., Seiki M., Ishii S., Fujinaga K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer 1998, 77:128-137.
14. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., Tamaki K. Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res. 2005, 33:3540-3549.
15. Wei G., Srinivasan R., Cantemir-Stone C.Z., Sharma S.M., Santhanam R., Weinstein M., Muthusamy N., Man A.K., Oshima R.G., Leone G., Ostrowski M.C. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 2009, 114:1123-1130.
16. Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010, 70:1501-1512.
17. Guenin S., Mauriat M., Pelloux J., Van Wuytswinkel O., Bellini C., Gutierrez L. Normalization of qRT-PCR data: the necessity of adopting a systematic, experimental conditions-specific, validation of references. J. Exp. Bot. 2009, 60:487-493.
18. Eckersberger E., Finkelstein J., Sadri H., Margreiter M., Taneja S.S., Lepor H., Djavan B. Screening for prostate cancer: a review of the ERSPC and PLCO Trials. Rev. Urol. 2009, 11:127-133.
19. Abdulla A., Kapoor A. Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can. Urol. Assoc. J. 2011, 5:120-133.
20. Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 2009, 6:76-85.
21. Fujita Y., Kojima K., Ohhashi R., Hamada N., Nozawa Y., Kitamoto A., Sato A., Kondo S., Kojima T., Deguchi T., Ito M. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J. Biol. Chem. 2010, 285:19076-19084.
22. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007, 67:955-967.
23. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. P53 mutations in human cancers. Science 1991, 253:49-53.
24. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
25. Kang J.H., Song K.H., Jeong K.C., Kim S., Choi C., Lee C.H., Oh S.H. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 2011, 11:334.
26. Eberhardt W., Schulze M., Engels C., Klasmeier E., Pfeilschifter J. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol. Endocrinol. 2002, 16:1752-1766.